DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

Phase 1

Completed

Conditions: Brain Tumor, Pediatric
Solid Tumor, Childhood
Lymphoma

Interventions: Drug: BMS-986378
Drug: BMS-986158

First Posted Date: 2019-05-03

Last Posted Date: 2024-10-02

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 41

Registration Number: NCT03936465

Locations: 🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States

and more 3 locations

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

Phase 1

Active, not recruiting

Conditions: Cutaneous Melanoma

Interventions: Drug: Nivolumab (480 mg infusion)
Biological: NeoVax plus Montanide
Drug: Ipilimumab

First Posted Date: 2019-04-26

Last Posted Date: 2024-10-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 11

Registration Number: NCT03929029

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Young, Empowered & Strong (YES): The Young Women's Breast Cancer Study 2- Focus on Intervention Pilot

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Other: YES portal

First Posted Date: 2019-04-12

Last Posted Date: 2023-04-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 30

Registration Number: NCT03913936

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Phase 1

Active, not recruiting

Conditions: Acute Myeloid Leukemia
Myeloproliferative Neoplasms
Chronic Myelomonocytic Leukemia
Myelofibrosis
Myelodysplastic Syndromes

Interventions: Drug: Ipilimumab
Biological: CD25hi Treg depleted DLI

First Posted Date: 2019-04-11

Last Posted Date: 2024-07-31

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 25

Registration Number: NCT03912064

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

Acceptance and Commitment Therapy (ACT) - Based Treatment Development for Cancer Patients Treated for Pain

Completed

Conditions: Cancer

Interventions: Behavioral: Acceptance & Commitment Therapy

First Posted Date: 2019-04-10

Last Posted Date: 2022-05-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT03910296

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Phase 2

Active, not recruiting

Conditions: Liposarcoma
Undifferentiated Pleomorphic Sarcoma
Sarcoma
Leiomyosarcoma

Interventions: Drug: Eribulin
Drug: Pembrolizumab

First Posted Date: 2019-04-02

Last Posted Date: 2024-12-03

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 57

Registration Number: NCT03899805

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital Cancer Center, Boston, Massachusetts, United States

Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer

Phase 2

Completed

Conditions: Head and Neck Cancer

Interventions: Drug: Nivolumab
Drug: Cisplatin
Drug: Docetaxel
Radiation: Intensity-modulated radiotherapy

First Posted Date: 2019-03-29

Last Posted Date: 2023-12-20

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 6

Registration Number: NCT03894891

Locations: 🇺🇸
The Tisch Cancer Institute, New York, New York, United States
🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸
Winship Cancer Institute, Atlanta, Georgia, United States

and more 1 locations

Personal Web Page In Clinical Trial Participant Education

Not Applicable

Completed

Conditions: Prostate Cancer
Kidney Cancer
Genitourinary Cancer

Interventions: Other: Postwire

First Posted Date: 2019-03-22

Last Posted Date: 2019-06-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 99

Registration Number: NCT03887091

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Study of De_Intensified Postoperative Radiation Therapy for HPV Associated Oropharyngeal Squamous Cell Carcinoma

Not Applicable

Recruiting

Conditions: Head and Neck Cancer

Interventions: Radiation: Radiation therapy

First Posted Date: 2019-03-15

Last Posted Date: 2024-03-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 111

Registration Number: NCT03875716

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Individualizing Surveillance Mammography for Older Breast Cancer Survivors

Not Applicable

Completed

Conditions: Breast Cancer

Interventions: Other: Communication Tool

First Posted Date: 2019-03-07

Last Posted Date: 2022-08-24

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 45

Registration Number: NCT03865654

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy